The benefits and risks of alemtuzumab in multiple sclerosis

被引：0
|
作者：
Ontaneda, Daniel [1 ]
Cohen, Jeffrey A. [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期
关键词：
alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;
D O I：
10.1586/ECI.13.1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [1] Alemtuzumab for Multiple Sclerosis
    Willis, Mark D.
    Robertson, Neil P.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)
  • [2] Alemtuzumab for the treatment of multiple sclerosis
    Willis, Mark D.
    Robertson, Neil P.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 525 - 534
  • [3] Alemtuzumab in Multiple Sclerosis
    Azzopardi, Laura
    Coles, Alasdair
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 79 - 82
  • [4] ALEMTUZUMAB: BENEFITS AND CHALLENGES OF NEW THERAPY IN MULTIPLE SCLEROSIS
    Illes Zsolt
    Tobias Sejbaek
    Csepany Tuende
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2015, 68 (5-6): : 155 - 164
  • [5] Drug safety evaluation of alemtuzumab for multiple sclerosis
    Willis, Mark
    Robertson, Neil P.
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (08) : 1115 - 1124
  • [6] Alemtuzumab Treatment of Multiple Sclerosis
    Coles, Alasdair F.
    SEMINARS IN NEUROLOGY, 2013, 33 (01) : 66 - 73
  • [7] Risks and benefits of multiple sclerosis therapies: need for continual assessment?
    Kieseier, Bernd C.
    Wiendl, Heinz
    Hartung, Hans-Peter
    Leussink, Verena-Isabell
    Stueve, Olaf
    CURRENT OPINION IN NEUROLOGY, 2011, 24 (03) : 238 - 243
  • [8] Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
    Havrdova, Eva
    Horakova, Dana
    Kovarova, Ivana
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 31 - 45
  • [9] Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients
    Kim, Hyunjin
    Lee, Eun-Jae
    Kim, Sung Keun
    Kim, Kwang-Kuk
    Lim, Young-Min
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 : 247 - 251
  • [10] Alemtuzumab for Multiple Sclerosis
    Mark D. Willis
    Neil P. Robertson
    Current Neurology and Neuroscience Reports, 2016, 16
12345